Explore

Fexofenadine Use: Key Interactions and Precautions for Allergy Relief

Fexofenadine Use: Key Interactions and Precautions for Allergy Relief

Fexofenadine, an antihistamine used for allergy relief, has several important interactions and precautions that users should be aware of. Notably, fruit juices like grapefruit, orange, and apple can significantly reduce the drug's absorption by up to 36%, impacting its effectiveness. It is recommended to take fexofenadine with water to avoid this interaction. Additionally, aluminum and magnesium-based antacids should be taken at least two hours apart from fexofenadine to prevent reduced drug levels. Prescription medications such as ketoconazole and erythromycin can increase fexofenadine levels, raising the risk of side effects, while rifampin can decrease its effectiveness. Alcohol and sedating medications may enhance drowsiness in sensitive individuals, despite fexofenadine's non-sedating design.

FDA Recalls Levothyroxine Sodium Tablets Due to Subpotency Concerns

FDA Recalls Levothyroxine Sodium Tablets Due to Subpotency Concerns

The Food and Drug Administration (FDA) has issued a Class II recall for certain lots of levothyroxine sodium tablets distributed by Major Pharmaceuticals. The recall is due to the tablets being 'subpotent,' meaning they may not deliver the full prescribed dose. Levothyroxine sodium is commonly used to treat underactive thyroid and goiter. The affected lots include 10-count blister packs and 100-tablet cartons with dosages ranging from 25 micrograms to 150 micrograms. The expiration dates for these lots range from July 2026 to January 2027. Patients are advised to check their medication against the FDA's list of affected lot numbers and consult their healthcare provider if there is a match. The FDA assures that any health effects from the lower dose are expected to be temporary and reversible.

FDA Advisers Vote to Add Peptides to Drug Compounding List Amid Controversy

FDA Advisers Vote to Add Peptides to Drug Compounding List Amid Controversy

The FDA's Pharmacy Compounding Advisory Committee has voted to add six peptides to a drug compounding list, allowing specialty pharmacies to use them in custom medications. The decision, which is non-binding, will require FDA approval. The peptides, including BPC-157 and TB-500, have gained popularity online despite limited clinical data. The vote has sparked debate between FDA scientists, who oppose the addition due to safety concerns, and committee members who argue it could reduce harm by steering consumers away from unregulated markets.

FDA Panel Supports Compounding of Select Peptides Amid Controversy

FDA Panel Supports Compounding of Select Peptides Amid Controversy

An FDA advisory panel has recommended allowing compounding pharmacies to manufacture the peptides epitalon and semax, while narrowly voting against emideltide. This decision follows a two-day meeting that highlighted tensions between the Make America Healthy Again movement and mainstream scientists. The panel's recommendations come despite FDA staff's concerns about the lack of clinical evidence for these peptides' safety and efficacy. The decision now awaits further action from the FDA, which may or may not follow the panel's advice.

FDA Advisers Support Looser Rules for Compounding Unapproved Peptides, Raising Safety Concerns

FDA Advisers Support Looser Rules for Compounding Unapproved Peptides, Raising Safety Concerns

The Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee recently voted in favor of allowing pharmacies to compound multiple unapproved peptides. This decision, made over a two-day meeting, has been met with enthusiasm from the wellness industry but has raised concerns within the medical community. Peptides, which are short strings of amino acids, are popular for their purported health benefits, including muscle recovery and longevity. Despite their popularity, the FDA had previously banned certain peptides due to potential safety risks, such as heart toxicity and infections. The committee's vote included approval for peptides like BPC-157 and TB-500, while others like emideltide were excluded. The FDA is not obligated to follow the committee's recommendations, but the decision highlights a growing demand for these compounds.

Dexlansoprazole Use Requires Awareness of Drug Interactions and Lifestyle Factors

Dexlansoprazole Use Requires Awareness of Drug Interactions and Lifestyle Factors

Dexlansoprazole, a proton pump inhibitor, requires careful management due to potential drug interactions and lifestyle factors. The medication can interact with drugs like clopidogrel, reducing its antiplatelet effect and increasing clot risk. Patients are advised to avoid crushing or chewing the capsules to maintain the dual delayed-release mechanism. Alcohol and certain foods can undermine the medication's goals by irritating the esophageal lining. Patients with a history of Clostridioides difficile infection or liver impairment may require additional monitoring.

Modafinil Use in Seniors: Considerations and Alternatives

Modafinil Use in Seniors: Considerations and Alternatives

Modafinil, known as Provigil, is a wakefulness-promoting agent prescribed for conditions like narcolepsy and sleep apnea-related sleepiness. It is sometimes used off-label for fatigue in seniors, but requires careful consideration due to age-related changes in drug metabolism and potential side effects. Seniors often face polypharmacy, increasing the risk of drug interactions. Modafinil can raise blood pressure and heart rate, posing risks for those with cardiovascular issues. Alternatives like optimizing CPAP therapy, reviewing current medications, and improving sleep hygiene are recommended before considering modafinil.

FDA Recalls Nationwide Allergy Medication Due to Potentially Life-Threatening Mix-Up

FDA Recalls Nationwide Allergy Medication Due to Potentially Life-Threatening Mix-Up

The FDA has announced a recall of an over-the-counter allergy medication sold nationwide due to a potentially life-threatening mix-up with another medication. The recall involves cetirizine hydrochloride tablets, commonly sold as a generic version of Zyrtec, which may be contaminated with ranitidine, a medication used to treat heartburn and ulcers. The issue was discovered by a pharmacy technician who noticed the wrong-colored pills in the bottles. Although no illnesses have been reported, the FDA warns that individuals with hypersensitivity to ranitidine could experience severe reactions, including anaphylaxis. The affected medication was distributed across several retailers, and consumers are advised to stop using the product immediately.

FDA Issues Nationwide Recall of Levothyroxine Sodium Tablets Due to Subpotency

FDA Issues Nationwide Recall of Levothyroxine Sodium Tablets Due to Subpotency

The Food and Drug Administration (FDA) has announced a nationwide recall of certain lots of levothyroxine sodium tablets distributed by Major Pharmaceuticals. These tablets, used to treat conditions such as hypothyroidism and goiter, were found to be subpotent, delivering less medication than intended. The recall affects tablets packaged in 10-count blister packs and 100-tablet cartons, with specific lot numbers and expiration dates provided by the FDA. The recall is classified as Class II, indicating that the subpotency may cause temporary, reversible health effects.

Doctors Exploit Regulatory Loophole to Prescribe Unauthorized Peptide BPC-157

Doctors Exploit Regulatory Loophole to Prescribe Unauthorized Peptide BPC-157

A CBC News investigation has revealed that some doctors in Canada are using a regulatory loophole to prescribe an unauthorized peptide, BPC-157, despite Health Canada's warnings. The peptide is promoted for muscle growth and tissue repair, but it lacks approval for safety, quality, or effectiveness. Doctors are able to prescribe BPC-157 as a compounded natural health product, which allows pharmacies to formulate it despite its unapproved status. The investigation found that some doctors are promoting these peptides to patients, capitalizing on their popularity among fitness enthusiasts. Health Canada has stated that BPC-157 is not authorized and its safety and efficacy have not been assessed.

Australian Regulator Warns of Eye Disorder Risk Linked to GLP-1 Drugs

Australian Regulator Warns of Eye Disorder Risk Linked to GLP-1 Drugs

The Therapeutic Goods Administration (TGA) in Australia has issued a warning about a rare but severe eye disorder associated with GLP-1 drugs, including Ozempic and Wegovy, used for type 2 diabetes and obesity treatment. The disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), can lead to permanent visual impairment. The TGA's warning follows reports of 36 cases linked to these medications. Despite the warning, the TGA does not recommend discontinuing the drugs without consulting a doctor, as the benefits of managing diabetes and obesity may outweigh the risks. Novo Nordisk, the manufacturer of these drugs, maintains that the benefit-risk profile remains favorable.

FDA Panel Supports Easier Access to Peptide Therapies Despite Safety Concerns

FDA Panel Supports Easier Access to Peptide Therapies Despite Safety Concerns

An advisory panel to the Food and Drug Administration (FDA) has recommended easing restrictions on peptide therapies, allowing specialized pharmacies to produce these compounds. Despite the FDA scientists' concerns about the lack of large-scale human trials and potential safety risks, the panel voted in favor of making peptides more accessible. The decision was influenced by the growing demand for peptides in athletic performance and longevity, as well as the need to regulate the unvetted substances currently available in the market. Health Secretary Robert F. Kennedy Jr. has publicly supported this move, emphasizing the importance of safe manufacturing processes.